InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.02
(
0.20%
)
US TECH 100
20,551.60
(
0.05%
)
Dow Jones
43,879.97
(
0.34%
)
Brent Oil
73.72
(
-2.31%
)
Bitcoin
75,879.23
(
-0.03%
)
Post# of 158400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

d5wr59mfi8

Send PM Follow Ignore
Followers 63
Posts 3150
Boards Moderated 0
Alias Born 03/06/2014

d5wr59mfi8

Re: cwwan1 post# 121200

Sunday, 03/23/2014 1:21:50 PM

Sunday, March 23, 2014 1:21:50 PM

Post# of 158400
It looks like Koos is planning on licensing HemaXellerate I, which IMO is the smartest thing he can do. Why settle for 1 billion, when you can make 10 billion in 10 years. Also I wonder about licensing and if it will legally protect us, where the licensee is responsible for issues with the treatment. If so, that would be a huge reduction in liability that a lot of Biotech Pharmaceutical companies face.

"The Company estimates that the total costs for initiating and completing Phase I, Phase II and Phase III clinical trials with regard to the HemaXellerate I product shall be $6,000,000. The Company’s current intention is to initiate and complete Phase I and Phase II clinical trials with regard to HemaXellerate I and, upon successful completion of a Phase II clinical trial, seek to license the product out to one or more licensees."

http://www.sec.gov/Archives/edgar/data/1589150/000155479514000018/regforms1a11014.htm

The opinions, comments, or concerns, expressed herein, are solely that of the screen name 'd5wr59mfi8'. They are not to be misconstrued as legal or financial advice and should not be followed. For financial advice, please see the guidance of financial p

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up